Search
for
Sort by
Research 241–270 of 1000+
- Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- Effect of C-ring modifications in benzo[c]quinolizin-3-ones, new selective inhibitors of human 5α-reductase 1
- Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta)
- Five-alpha-reductase Inhibitors for prostate cancer prevention.
- Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
- Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
- Synthesis of phenanthridin-3-one derivatives: Non-steroidal inhibitors of steroid 5-α-reductase
- Long-Term Experience With 5-alpha-Reductase Inhibitors.
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- The efficacy of topical minoxidil 2% versus topical botanically derived inhibitors of 5 alpha reductase in treatment of female pattern hair loss by trichoscopy
- 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- 5-alpha reductase inhibitors use in prostatic disease and beyond
- Finasteride prescribed for hair loss consistently leads to depression. Comment on ‘Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement’
- Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
- Long-term Treatment with a 5-Alpha-Reductase Inhibitor AlleviatesDepression-like Behavior in Obese Male Rats
- Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
- Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
- BH02 Reversibility of 5-alpha reductase inhibitor effects on semen parameters: a review of human evidence
- Evaluation of 5α-reductase inhibitory activity of certain herbs useful as antiandrogens
- Extensive Challenges and Pending Advances in the Study of 5-Alpha-Reductase Isoenzymes. A Literature Review
- 5 Alpha-Reductase Inhibitory Potential of Solanum nigrum Effective for Management of Alopecia
- The connection of 5-alpha reductase inhibitors to the development of depression
- Inhibition of skin 5α-reductase by oral contraceptive progestins<i>in vitro</i>
- Inhibition of 5α-Reductase, IL-6 Secretion, and Oxidation Process of Equisetum debile Roxb. ex Vaucher Extract as Functional Food and Nutraceuticals Ingredients